Icare USA, Inc.

iCare is a leading ophthalmic diagnostics and screening company specializing in handheld and automated devices for detection and monitoring of glaucoma, diabetic retinopathy, and age-related macular degeneration (AMD). The company manufactures a comprehensive product line including rebound tonometers (IOP measurement devices), confocal fundus imaging systems with TrueColor technology, automated perimetry systems with active retinal tracking, and microperimetry devices. iCare's product portfolio includes the iCare IC200 handheld tonometer (market leader in rebound tonometry with validation from over 300 clinical studies), iCare EIDON Family confocal imaging systems offering ultra-high-quality detail-rich images from posterior pole to periphery, iCare COMPASS automated perimeter combining visual field testing with retinal tracking and non-mydriatic imaging, iCare MAIA microperimetry system for mesopic confocal analysis, iCare ST500 slit lamp tonometer, and iCare ILLUME screening solution featuring AI-assisted automated imaging and processing for early detection of retinal diseases. The company also offers iCare Screening Solution, a fully automated AI-assisted system for preventive eye care. All devices are designed for ease of use with minimal training, non-mydriatic capability, and intuitive interfaces. iCare is part of the Revenio Group, which includes Icare Finland Oy, Icare USA Inc., iCare World Australia, China iCare Medical Technology, Thirona RetinaB.V., and Centervue S.P.A. The company serves ophthalmologists, optometrists, general practitioners, and diabetic clinics globally. Clinical evidence and regulatory compliance underpin all product development.